Avacta's Chief Scientific Officer to Present at Major US Conference
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its Chief Scientific Officer, Dr Amrik Basran, will be presenting at the Next Generation Protein Therapeutics & Bioconjugates conference in San Francisco, California on 19 June 2019.
Dr Basran's presentation, 'Affimer Therapeutics: A Novel Human Scaffold for the Generation of Bi-specific Molecules', will give an overview of the benefits of using Affimer technology to generate bispecific drug molecules.
Bispecific therapy - single molecules that engage with two drug targets simultaneously - is a major area of focus in large pharma immuno-oncology programmes. Avacta has highlighted bispecifics as a key element of its therapeutic pipeline strategy, alongside the development of its novel tumour microenvironment activated drug conjugates.
Dr Basran's presentation will highlight the stability, solubility and ease of manufacturing functional Affimer bispecifics incorporating Avacta's proprietary serum half-life extension technology (Affimer XTTM), as well as PD-L1 and LAG-3 Affimer inhibitors.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Top stories from the Proactive Investors UK newsroom.
ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...